These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 16139813)

  • 1. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study.
    Pollack MH; Simon NM; Zalta AK; Worthington JJ; Hoge EA; Mick E; Kinrys G; Oppenheimer J
    Biol Psychiatry; 2006 Feb; 59(3):211-5. PubMed ID: 16139813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
    Ammar G; Naja WJ; Pelissolo A
    Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression.
    Keck PE; Corya SA; Altshuler LL; Ketter TA; McElroy SL; Case M; Briggs SD; Tohen M
    J Clin Psychiatry; 2005 May; 66(5):611-6. PubMed ID: 15889948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.
    Thase ME; Corya SA; Osuntokun O; Case M; Henley DB; Sanger TM; Watson SB; Dubé S
    J Clin Psychiatry; 2007 Feb; 68(2):224-36. PubMed ID: 17335320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
    Corya SA; Williamson D; Sanger TM; Briggs SD; Case M; Tollefson G
    Depress Anxiety; 2006; 23(6):364-72. PubMed ID: 16710853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.
    Andersen SW; Clemow DB; Corya SA
    J Clin Psychiatry; 2005 Nov; 66(11):1468-76. PubMed ID: 16420086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.
    Corya SA; Perlis RH; Keck PE; Lin DY; Case MG; Williamson DJ; Tohen MF
    J Clin Psychiatry; 2006 May; 67(5):798-806. PubMed ID: 16841630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.
    Shelton RC; Williamson DJ; Corya SA; Sanger TM; Van Campen LE; Case M; Briggs SD; Tollefson GD
    J Clin Psychiatry; 2005 Oct; 66(10):1289-97. PubMed ID: 16259543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
    Silverstone PH; Salinas E
    J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.
    Lorenz RA; Jackson CW; Saitz M
    Pharmacotherapy; 2010 Sep; 30(9):942-51. PubMed ID: 20795849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression.
    Brown EB; McElroy SL; Keck PE; Deldar A; Adams DH; Tohen M; Williamson DJ
    J Clin Psychiatry; 2006 Jul; 67(7):1025-33. PubMed ID: 16889444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of treatments for refractory generalized anxiety disorder: a systematic review.
    Samuel M; Zimovetz EA; Gabriel Z; Beard SM
    Int Clin Psychopharmacol; 2011 Mar; 26(2):63-8. PubMed ID: 21088608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.
    Poyurovsky M; Pashinian A; Gil-Ad I; Maayan R; Schneidman M; Fuchs C; Weizman A
    Am J Psychiatry; 2002 Jun; 159(6):1058-60. PubMed ID: 12042201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine augmentation of fluoxetine in body dysmorphic disorder.
    Phillips KA
    Am J Psychiatry; 2005 May; 162(5):1022-3. PubMed ID: 15863817
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study.
    Stein MB; Kline NA; Matloff JL
    Am J Psychiatry; 2002 Oct; 159(10):1777-9. PubMed ID: 12359687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
    J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction.
    Amsterdam JD; Shults J
    J Affect Disord; 2005 Jul; 87(1):121-30. PubMed ID: 15923042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study.
    McIntyre A; Gendron A; McIntyre A
    Depress Anxiety; 2007; 24(7):487-94. PubMed ID: 17177199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial.
    Michelson D; Kociban K; Tamura R; Morrison MF
    J Psychiatr Res; 2002; 36(3):147-52. PubMed ID: 11886692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.